Durvalumab

ClinicalJuly 29, 2026

Phase I Trial of Durvalumab and Olaparib with Radiation for Unresectable Pancreatic Cancer

A phase I trial is underway to evaluate the safety and tolerability of olaparib combined with durvalumab and radiation therapy in patients with locally advanced unresectable pancreatic cancer.

Sponsor company

Mechanism of action

Recent signals(8)

Phase I Trial of Durvalumab and Olaparib with Radiation for Unresectable Pancreatic Cancer

AstraZeneca's Study on Durvalumab and Tremelimumab in HCC with TACE

Durvalumab and Cetuximab Combination Trial for Head and Neck Cancer

Merck's Calderasib and Durvalumab Trial for KRAS G12C NSCLC Enters Phase

Phase III Trial of Durvalumab Post-Surgery in Early-Stage NSCLC Shows Potential Benefit

Study on Durvalumab, Bevacizumab, and TACE for Advanced Hepatocellular Carcinoma

Phase III Study of Durvalumab + Domvanalimab in Stage III Unresectable NSCLC Initiated

Phase III Trial of Durvalumab with Chemotherapy in Stage II-III Breast Cancer

Upcoming milestones

Related catalysts

Indications

Therapeutic areas

Get signals before the market moves